Appili Therapeutics Inc Class A (APLI) AI Stock Analysis

• Market Cap: C$2.57M
• Dividend Yield: N/A
• Average Volume (3M): 72.91K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.06
• Revenue Growth: -58.01%
• EPS Growth: 29.73%
• Country: CA
• Employees: 8
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 128,366,120
• 10 Day Avg. Volume: 40,186
• 30 Day Avg. Volume: 72,908
• PEG Ratio: 0.02
• Price to Book (P/B): -0.39
• Price to Sales (P/S): 5.13
• P/FCF Ratio: -1.70
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: C$0.01 ▼(-30.00% Downside)
• Action: Reiterated Date: 02/18/26
• Date: Action: Reiterated 02/18/26

The score is held down primarily by weak financial performance, especially negative equity, substantial losses, and reliance on external funding. Technicals are also mildly bearish (negative MACD and below key moving averages), while valuation signals are not supportive due to negative earnings and no dividend yield data.

Positive Factors

Focused infectious-disease pipeline

Appili’s concentration on antifungal and antibacterial clinical candidates (ATI-2307, ATI-1501) represents a durable strategic focus in a high-barrier therapeutic niche. Specialized anti-infective programs can attract non-dilutive government funding, long-term partnerships, and regulatory priority pathways, supporting sustained development momentum and strategic optionality over multiple quarters.

Strong reported revenue growth rate

A ~72% reported revenue growth rate indicates improving top-line momentum tied to program activity or contract/grant recognition. While absolute revenue is small, the trend signals commercial/contract progress and strengthens the company's ability to justify continued investment, partner interest, and resource allocation across clinical milestones.

Improving cash-flow trend

Cash generation has materially improved versus earlier periods, with TTM operating and free cash flow near breakeven. This trend reflects better cost control or timing of funding and extends runway, reducing immediate refinancing urgency and providing a firmer short-to-medium term base for completing planned clinical milestones.

Negative Factors

Stressed balance sheet

Negative shareholders’ equity and sizeable debt relative to a very small asset base create structural financial fragility. This limits flexibility to fund concurrent programs, increases refinancing and covenant risk, and elevates the likelihood of dilutive capital raises or onerous financing terms until clinical progress materially de-risks the pipeline.

Persistent operating losses

Sustained operating losses and a deeply negative net income profile mean the company cannot self-fund development. Continued negative margins drain resources, constrain investment in additional indications or larger trials, and make the company dependent on external capital or partner deal economics to advance programs long term.

Dependence on external funding model

As a pre-commercial biotech, Appili relies on grants, collaborations, and equity financing rather than recurring product revenue. This structural dependence exposes the company to capital-market cyclicality and dilution risk, and ties program continuity to the timing and availability of non-dilutive support or partner deals until commercialization is achieved.

Appili Therapeutics Inc Class A Business Overview & Revenue Model

Company Description

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.

How the Company Makes Money

Appili Therapeutics generates revenue primarily through the development and commercialization of its pharmaceutical products. The company earns money by securing funding from government grants, partnerships, and collaborations with larger pharmaceutical companies that provide resources and capital to support its research and development efforts. Additionally, Appili may receive milestone payments and royalties from partners upon the successful development and commercialization of their products. Their revenue model is further supported by potential sales of their therapies once they receive regulatory approval and are brought to market.

Appili Therapeutics Inc Class A Financial Statement Overview

Summary

Overall financial quality is weak: revenue remains very small (~$0.21M TTM), profitability is deeply negative (about -$3.0M TTM net income), and the balance sheet is highly stressed with negative shareholders’ equity and sizable debt (~$12.5M TTM) versus a very small asset base. Cash flow has improved versus prior years but is still slightly negative and not consistently self-funding.

Income Statement

TTM (Trailing-Twelve-Months) revenue is very small (~$0.21M) despite strong percentage growth, which reflects a low base rather than meaningful scale. Profitability remains weak: net income is deeply negative (about -$3.0M TTM) with a sharply negative net margin, and operating losses persist (negative EBIT and EBITDA margins). A key positive is the high reported gross margin, but it is not translating into sustainable bottom-line performance.

Balance Sheet

The balance sheet is stressed, highlighted by negative shareholders’ equity in the most recent periods (including TTM), which increases financial risk and limits flexibility. Debt is sizable (~$12.5M TTM) relative to a very small asset base (total assets well under $1M TTM), suggesting a thin balance sheet. While leverage looked healthier in 2021 (positive equity), the subsequent shift to negative equity indicates material deterioration over time.

Cash Flow

Cash generation is inconsistent. TTM (Trailing-Twelve-Months) operating and free cash flow are slightly negative (around -$0.02M), which is better than several prior years with large cash burn, but the reported free cash flow growth is sharply negative versus the prior period. The company is still not demonstrating durable self-funding capacity, and cash flow remains sensitive to timing and funding needs.

Breakdown	TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2020	Jun 2019
Income Statement
Total Revenue	206.31K	100.44K	334.18K	1.39M	0.00	199.11K
Gross Profit	199.58K	100.44K	327.91K	1.39M	-14.84K	199.11K
EBITDA	-1.59M	360.57K	-8.10M	-23.51M	-14.87M	-5.63M
Net Income	-2.96M	-2.62M	-9.24M	-25.12M	-14.33M	-5.42M
Balance Sheet
Total Assets	547.91K	3.03M	3.13M	8.28M	18.32M	11.17M
Cash, Cash Equivalents and Short-Term Investments	212.75K	1.23M	2.47M	6.66M	16.12M	10.54M
Total Debt	12.46M	12.29M	7.67M	4.98M	1.03M	1.00M
Total Liabilities	16.93M	16.43M	10.53M	11.55M	5.56M	2.33M
Stockholders Equity	-16.38M	-13.40M	-7.40M	-3.27M	12.75M	8.85M
Cash Flow
Free Cash Flow	-24.57K	866.46K	-10.10M	-19.08M	-11.46M	-4.26M
Operating Cash Flow	-24.57K	868.82K	-10.10M	-19.08M	-11.45M	-4.26M
Investing Cash Flow	0.00	-2.36K	-3.17K	5.06M	-4.99M	-1.14K
Financing Cash Flow	-18.17K	193.68K	5.91M	9.56M	17.02M	9.36M

Appili Therapeutics Inc Class A Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:APLI, the sentiment is Neutral. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 51.10 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:APLI.

Appili Therapeutics Inc Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VXL	43 Neutral	C$557.76K	-6.34	-10.82%	―	―	46.32%
APLI	42 Neutral	C$2.57M	-0.84	―	―	-58.01%	29.73%
XRTX	42 Neutral	C$4.18M	-0.98	-96.61%	―	―	-1939.32%
MIR	42 Neutral	C$45.61M	-17.16	―	―	-41.70%	-35.42%
KNE	41 Neutral	C$6.36M	-3.10	―	―	―	―
BIOV	29 Underperform	C$3.06M	-1.60	―	―	―	25.09%

Appili Therapeutics Inc Class A Corporate Events

Appili Therapeutics Raises C$100,000 in Second Tranche of Private Placement

Appili Therapeutics Inc., a Halifax-based biopharmaceutical company specializing in anti-infective therapies and medical countermeasures, has built a diversified portfolio that includes an FDA-approved metronidazole suspension for resistant infections. Its pipeline also features a tularemia vaccine candidate, addressing a significant biological weapon threat, and a topical antiparasitic treatment for cutaneous leishmaniasis.

The company has closed the second tranche of its non-brokered private placement, raising C$100,000 through the issuance of 4,000,000 units priced at C$0.025, each comprising one Class A common share and half of a warrant. Proceeds will support working capital and development of product candidates, while both investor warrants and broker warrants will remain subject to shareholder approval before becoming exercisable, underscoring the ongoing role of equity financing in Appili’s growth and clinical advancement strategy.

Appili also compensated finders with cash and broker warrants, which similarly require shareholder approval and will be subject to statutory hold periods. The structure of this financing, including conditional warrant exercisability and regulatory-imposed hold periods, reflects the company’s reliance on capital markets to fund its infectious disease programs while aligning with Toronto Stock Exchange requirements.

The most recent analyst rating on (TSE:APLI) stock is a Sell with a C$0.02 price target. To see the full list of analyst forecasts on Appili Therapeutics Inc Class A stock, see the TSE:APLI Stock Forecast page.

Appili Deepens Non-Dilutive Funding Base as Infectious Disease Pipeline Advances

Appili reported third-quarter fiscal 2026 results that underscore its strategy of leveraging non-dilutive government funding and partnerships to advance its infectious disease and biodefense pipeline. The company has secured more than US$75 million in cumulative government support and has a further US$82 million in proposals under review, supporting activities from manufacturing to clinical trial preparation while limiting shareholder dilution.

Pipeline progress featured the ATI-1801 topical antiparasitic program for cutaneous leishmaniasis, which now has a clearly defined U.S. regulatory path toward a potential NDA, with efforts underway to secure additional global health funding. Commercially, LIKMEZ, the first FDA-approved liquid oral formulation of metronidazole, is showing steady U.S. sales growth and is protected by patents extending to 2039, offering a growing royalty and milestone revenue stream.

In biodefense, ATI-1701, a tularemia vaccine candidate, reached a key milestone with successful GMP manufacturing of drug substance and product, positioning it for Phase 1 clinical use. The most significant new funding event was a contract of up to US$40 million from NIAID to advance VXV-01, a dual-antigen vaccine targeting multidrug-resistant Candida, where Appili leads development and holds an exclusive option to acquire global rights, potentially cementing its role in the emerging fungal vaccine field.

The most recent analyst rating on (TSE:APLI) stock is a Hold with a C$0.02 price target. To see the full list of analyst forecasts on Appili Therapeutics Inc Class A stock, see the TSE:APLI Stock Forecast page.

Appili Therapeutics Raises C$177,500 in First Tranche of Private Placement

Appili Therapeutics has closed the first tranche of its previously announced non-brokered private placement, raising C$177,500 through the issuance of 7.1 million units priced at C$0.025 each, with each unit comprising one Class A common share and one-half of a common share purchase warrant. The warrants, along with additional broker warrants issued as part of finder compensation, will only become exercisable upon receiving requisite shareholder approval under Toronto Stock Exchange rules, with all securities subject to a four-month-plus-one-day hold period; the company plans a second tranche of the financing later in December 2025 and intends to use the proceeds primarily for working capital and to advance its pipeline of infectious disease product candidates, underscoring its ongoing need for capital to support development in a highly specialized biopharmaceutical niche.

The most recent analyst rating on (TSE:APLI) stock is a Hold with a C$0.03 price target. To see the full list of analyst forecasts on Appili Therapeutics Inc Class A stock, see the TSE:APLI Stock Forecast page.